ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505

Also written as “REGN15505”, “REGN15505+Cemiplimab” and “REGN15505+REGN4336”.

Its studies are mostly in Carcinoma, Renal Cell, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since May 11, 20261 company-led study, 1 open or runningNext primary completion: Oct 27, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals11 open or runningphase 2since May 11, 2026May 11, 2026Oct 27, 2030phase 2 · NCT07594106

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2026First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT07594106 · 265 planned · United States

Ahead

  1. Oct 27, 2030Primary completion: phase 2 study in Carcinoma, Renal CellNCT07594106

TargetBeta

“A bispecific antibody directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the immune co-stimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07594106Carcinoma, Renal Cell · United States2RecruitingOct 27, 2030265

How it is read

Names in the registry

  • “REGN15505”, 1 entry
  • “REGN15505+Cemiplimab”, 1 entry
  • “REGN15505+REGN4336”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.